< back
1
#alzheimers
1
From pharmacytimes.com
FDA Approves Donanemab-Azbt for Early Symptomatic Alzheimer Disease
1 1
Donanemab-azbt is the first and only amyloid plaque targeting therapy that supports stopping therapy when the plaque is removed.
#lev #longevity #alzheimers #senescence #stopbreedingnow
7h ago
Showing first 1 out of 1